RxDoctor Payments Data

Melania Napolitano

Optometrist · Middle Village, NYNPI 1750572459

Payments from drug & device makers

$1,775in general payments, 2019–2025

Across 73 payments — averaging $24.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$337
  • Coopervision Inc.$330
  • Topcon Healthcare, Inc.$215
  • Bausch & Lomb Americas Inc.$163
  • Sight Sciences, Inc.$159
  • Novartis$152
  • plus $419 from 11 others

What the payments were for

  • Food & beverage$1,775100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,775 in reported general payments places this provider in the 75th percentile of 2,743 optometrist providers in New York.

See all optometrist providers in New York

Medicare billing

Part B allowed, 2024
$99,274
Medicare patients
233
Services billed
1,149

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine103$110,768
XiidraLifitegrast94$109,490
LumiganBimatoprost33$20,067
RocklatanNetarsudil Mesylat/Latanoprost25$10,016
CombiganBrimonidine Tartrate/Timolol14$8,614
Cyclosporine23$6,748
Travoprost39$6,126
Alphagan PBrimonidine Tartrate11$5,066
SimbrinzaBrinzolamide/Brimonidine Tart16$3,220
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol27$3,119
Loteprednol Etabonate19$2,054
Latanoprost170$1,142
Brimonidine Tartrate30$843
Tobramycin-DexamethasoneTobramycin/Dexamethasone21$761
Timolol Maleate42$599

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra$163$109,49094 claims
Aerie Pharmaceuticals, Inc.Rocklatan$44$10,01625 claims
AlconSimbrinza$52$3,22016 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$13$2,05419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,743 optometrist providers in New York.

Other optometrist in Middle Village

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →